Nextcure Inc (NASDAQ: NXTC) has seen a decline in its stock price by -18.80 in relation to its previous close of 0.68. However, the company has experienced a 4.64% gain in its stock price over the last five trading sessions. reuters.com reported 2025-06-16 that Drug developer NextCure said on Monday it had signed a deal worth up to $745 million with China-based drugmaker Simcere Zaiming to develop a cancer therapy for solid tumors.
Is It Worth Investing in Nextcure Inc (NASDAQ: NXTC) Right Now?
Moreover, the 36-month beta value for NXTC is 1.08. Analysts have varying opinions on the stock, with 0 analysts rating it as a “buy,” 2 as “overweight,” 0 as “hold,” and 0 as “sell.”
The public float for NXTC is 21.44M and currently, short sellers hold a 0.33% of that float. On June 16, 2025, NXTC’s average trading volume was 189.97K shares.
NXTC’s Market Performance
NXTC stock saw an increase of 4.64% in the past week, with a monthly gain of 34.22% and a quarterly increase of -13.66%. The volatility ratio for the week is 3.26%, and the volatility levels for the last 30 days are 4.69% for Nextcure Inc (NXTC). The simple moving average for the last 20 days is 6.21% for NXTC stock, with a simple moving average of -38.12% for the last 200 days.
Analysts’ Opinion of NXTC
Ladenburg Thalmann, on the other hand, stated in their research note that they expect to see NXTC reach a price target of $16. The rating they have provided for NXTC stocks is “Buy” according to the report published on March 01st, 2022.
Truist gave a rating of “Buy” to NXTC, setting the target price at $19 in the report published on March 05th of the previous year.
NXTC Trading at 23.41% from the 50-Day Moving Average
After a stumble in the market that brought NXTC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -69.61% of loss for the given period.
Stock Fundamentals for NXTC
The total capital return value is set at -0.86. Equity return is now at value -63.94, with -54.33 for asset returns.
Based on Nextcure Inc (NXTC), the company’s capital structure generated 0.08 points at debt to capital in total, while cash flow to debt ratio is standing at -8.38.
Currently, EBITDA for the company is -52.79 million with net debt to EBITDA at 0.34. The liquidity ratio also appears to be rather interesting for investors as it stands at 10.26.
Conclusion
To wrap up, the performance of Nextcure Inc (NXTC) has been mixed in recent times. The stock has received a mixed of “buy” and “hold” ratings from analysts. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
